Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | GLP1R | P43220 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613427 | 0.98 | FAAH (0.62) | FAAHEPHX2CASP2NAAAEPHX1 | |
| SCHEMBL17817086 | 0.98 | FAAH (0.62) | FAAHEPHX2CASP2NAAAEPHX1 | |
| SCHEMBL17817084 | 0.98 | FAAH (0.62) | FAAHEPHX2CASP2NAAAEPHX1 | |
| SCHEMBL24622918 | 0.98 | FAAH (0.62) | FAAHEPHX2CASP2NAAAEPHX1 | |
| SCHEMBL3273924 | 0.94 | FAAH (0.51) | FAAHEPHX2CASP2NAAAEPHX1 | |
| SCHEMBL13857031 | 0.92 | FAAH (0.67) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL21096710 | 0.90 | FAAH (0.65) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL27986572 | 0.90 | FAAH (0.70) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL9356724 | 0.90 | MEN1 (0.44) | FAAHEPHX2CASP2GLP1RMEN1 | |
| SCHEMBL15552174 | 0.88 | ALDH1A1 (0.48) | FAAHEPHX2CASP2GLP1RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150540-A1 | HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022087317-A1 | THIOHYDROXYPYRIDINE CHELATES | LUMIPHORE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3129350-B1 | MACROCYCLES | LUMIPHORE INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210290787-A1 | MACROCYCLE CONJUGATES | LUMIPHORE, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-2816038-B1 | HOPO CHELATORS | LUMIPHORE INC (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2019173639-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-2920157-B1 | DI-MACROCYCLES | LUMIPHORE INC (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018045385-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2423201-B1 | Luminescent macrocyclic lanthanide complexes | UNIV CALIFORNIA (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20160221971-A1 | DI-MACROCYCLES | LUMIPHORE, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9273059-B2 | Macrocyclic HOPO chelators | LUMIPHORE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150157746-A1 | MACROCYCLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-11 | — | — | US | disclosed |
| EP-2816038-A1 | Hopo chelators | Lumiphore, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2470513-B1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8729258-B2 | Luminescent macrocyclic lanthanide complexes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120329174-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-27 | — | — | US | disclosed |
| US-8173800-B2 | Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2423201-A1 | Luminescent macrocyclic lanthanide complexes | The Regents of The University of California (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20080213917-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213917-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | SSB, HACD3, CLTA | FAAH 1287/4885EPHX2 2965/4885CASP2 2679/4885 |
| US-20210290787-A1 | MACROCYCLE CONJUGATES | FOLH1, KLK3, CD47 | FAAH 4170/4885EPHX2 2132/4885CASP2 3704/4885 |
| US-20160221971-A1 | DI-MACROCYCLES | DLD, NDC1, MCL1 | FAAH 4748/4885EPHX2 1930/4885CASP2 1035/4885 |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | FAAH 4839/4885EPHX2 3366/4885CASP2 3804/4885 |
| US-20120329174-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | SSB, HACD3, CLTA | FAAH 1287/4885EPHX2 2965/4885CASP2 2679/4885 |
| US-20150157746-A1 | MACROCYCLES | SLC39A14, SLC39A3, SLC40A1 | FAAH 4686/4885EPHX2 3539/4885CASP2 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.